Phase I/II trial of imatinib and temozolomide in advanced unresectable melanoma

Authors:
  • LFL. A. Fecher
    L. A. Fecher
  • KNK. Nathanson
    K. Nathanson
  • KFK. T. Flaherty
    K. T. Flaherty
  • RAR. Amaravadi
    R. Amaravadi
  • LGL. Giles
    L. Giles
  • SMS. McGettigan
    S. McGettigan
  • MCM. Carberry
    M. Carberry
  • DED. Elder
    D. Elder
  • LSL. Schuchter
    L. Schuchter

Abstract
9059 Background: Imatinib mesylate (I) is a selective tyrosine kinase inhibitor targeting c-KIT, PDGFR, and others. Preclinical studies suggest activity against melanoma (M). Recent data showed c-KIT mutations or increased copy number in mucosal, acral, ocular, and chronic sun damaged (CSD) M, but not in non-CSD M. Methods: This ongoing phase I/II study was initiated to define safety and MTD of I in combination with temozolomide (T) in pts with unresectable, stage III/IV M and to determine preliminary efficacy. I is given daily from D1 and T is given daily on D1–5, every 28 days. Responses assessed every 2 cycles per RECIST. No prior treatment with T allowed. Correlative studies: c-KIT expression and genotyping on pre-treatment tumor samples. As trial was ongoing when c-KIT data became available, pts with acral, mucosal, ocular, and CSD M were preferentially enrolled onto phase II portion. Results: To date, 24 pts enrolled and 23 treated; phase I: 16 with cutaneous M treated in 5 dose level cohorts and ph...